Drug major Dr Reddy’s Laboratories on Thursday announced the launch of Sevelamer Carbonate for oral suspension, used for controlling serum phosphorus in patients with chronic kidney disease on dialysis, in the US market. The newly launched product is in the strengths of 0.8 g and 2.4 g packets, and is a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the US Food and Drug Administration, Dr Reddy’s Laboratories said in a BSE filing.